Putting guidelines into practice: has the era of perioperative chemotherapy arrived?
作者信息
Georgiou Chloe L, Pezaro Carmel, Sengupta Shomik
机构信息
Department of Medical Oncology, Eastern Health, Box Hill, Victoria, Australia.
Eastern Health Clinical School, Monash University, Box Hill, Victoria, Australia.
出版信息
Transl Androl Urol. 2018 May;7(Suppl 2):S255-S257. doi: 10.21037/tau.2018.04.02.
Abstract
摘要
相似文献
1
Putting guidelines into practice: has the era of perioperative chemotherapy arrived?将指南付诸实践：围手术期化疗时代已经到来了吗？
Transl Androl Urol. 2018 May;7(Suppl 2):S255-S257. doi: 10.21037/tau.2018.04.02.
2
Practice guidelines for perioperative transesophageal echocardiography: recommendations of the Indian association of cardiovascular thoracic anesthesiologists.围手术期经食管超声心动图实践指南：印度心血管胸科麻醉医师协会的建议
Ann Card Anaesth. 2013 Oct-Dec;16(4):268-78. doi: 10.4103/0971-9784.119175.
3
[Historical evolution and research progress of perioperative therapy of locally advanced gastric cancer].[局部进展期胃癌围手术期治疗的历史演变与研究进展]
Zhonghua Wei Chang Wai Ke Za Zhi. 2019 Feb 25;22(2):196-200.
4
Introducing national guidelines on perioperative chemotherapy for gastric cancer in Norway: a retrospective audit.挪威引入胃癌围手术期化疗国家指南：回顾性审计。
Eur J Surg Oncol. 2010 Jul;36(7):610-6. doi: 10.1016/j.ejso.2010.05.006.
5
Perioperative beta-blockade: guidelines and practice in New Zealand.围手术期β受体阻滞剂：新西兰的指南与实践
Anaesth Intensive Care. 2005 Oct;33(5):645-50. doi: 10.1177/0310057X0503300515.
6
Perioperative chemotherapy for bladder cancer in the general population: Are practice patterns finally changing?普通人群膀胱癌的围手术期化疗：实践模式终于在改变了吗？
Urol Oncol. 2018 Mar;36(3):89.e13-89.e20. doi: 10.1016/j.urolonc.2017.11.015. Epub 2017 Dec 15.
7
Society of Onco-Anaesthesia and Perioperative Care consensus guidelines for perioperative management of patients for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC).肿瘤麻醉与围手术期护理学会关于减瘤手术和热灌注化疗（CRS-HIPEC）患者围手术期管理的共识指南。
Indian J Anaesth. 2019 Dec;63(12):972-987. doi: 10.4103/ija.IJA_765_19. Epub 2019 Dec 11.
8
Perioperative tobacco use treatments: putting them into practice.围手术期烟草使用治疗：付诸实践。
BMJ. 2017 Sep 6;358:j3340. doi: 10.1136/bmj.j3340.
9
Putting the E (evidence) in a new Era for myeloma.将“证据”引入骨髓瘤的新时代。
Leuk Lymphoma. 2011 Mar;52(3):349-50. doi: 10.3109/10428194.2011.557170.
10
Universal testing of colorectal cancer for deficient mismatch repair - a new era has arrived.对结直肠癌进行错配修复缺陷的普遍检测——新时代已经到来。
Colorectal Dis. 2017 Sep;19(9):801-802. doi: 10.1111/codi.13784.
引用本文的文献
1
Trends in utilization of neoadjuvant and adjuvant chemotherapy for muscle invasive bladder cancer.新辅助化疗和辅助化疗在肌层浸润性膀胱癌中的应用趋势。
Investig Clin Urol. 2020 Nov;61(6):565-572. doi: 10.4111/icu.20200132. Epub 2020 Sep 8.
本文引用的文献
1
Clinical need for standardised multidisciplinary meeting assessment processes.
Intern Med J. 2018 Feb;48(2):230-231. doi: 10.1111/imj.13688.
2
Perioperative chemotherapy for bladder cancer in the general population: Are practice patterns finally changing?普通人群膀胱癌的围手术期化疗：实践模式终于在改变了吗？
Urol Oncol. 2018 Mar;36(3):89.e13-89.e20. doi: 10.1016/j.urolonc.2017.11.015. Epub 2017 Dec 15.
3
Bladder cancer: diagnosis and management of bladder cancer: © NICE (2015) Bladder cancer: diagnosis and management of bladder cancer.膀胱癌：膀胱癌的诊断与管理：© 英国国家卫生与临床优化研究所（2015年）膀胱癌：膀胱癌的诊断与管理
BJU Int. 2017 Dec;120(6):755-765. doi: 10.1111/bju.14045.
4
Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline.非转移性肌肉浸润性膀胱癌治疗：AUA/ASCO/ASTRO/SUO 指南。
J Urol. 2017 Sep;198(3):552-559. doi: 10.1016/j.juro.2017.04.086. Epub 2017 Apr 26.
5
Emerging role of checkpoint inhibition in localized bladder cancer.检查点抑制在局限性膀胱癌中的新作用。
Urol Oncol. 2016 Dec;34(12):548-555. doi: 10.1016/j.urolonc.2016.09.004. Epub 2016 Oct 21.
6
Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis.肌肉浸润性膀胱癌的新辅助化疗：系统评价和两步荟萃分析
Oncologist. 2016 Jun;21(6):708-15. doi: 10.1634/theoncologist.2015-0440. Epub 2016 Apr 6.
7
Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer.DNA修复基因缺陷可预测肌层浸润性膀胱癌对基于顺铂的新辅助化疗的反应。
Eur Urol. 2015 Dec;68(6):959-67. doi: 10.1016/j.eururo.2015.07.009. Epub 2015 Aug 1.
8
Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial.根治性膀胱切除术治疗 pT3-pT4 或 N+M0 膀胱尿路上皮癌患者中即刻与延迟化疗的比较（EORTC 30994）：一项国际多中心、开放标签、随机 3 期临床试验。
Lancet Oncol. 2015 Jan;16(1):76-86. doi: 10.1016/S1470-2045(14)71160-X. Epub 2014 Dec 11.
9
Perioperative chemotherapy for muscle-invasive bladder cancer: A population-based outcomes study.肌层浸润性膀胱癌的围手术期化疗：基于人群的结局研究。
Cancer. 2014 Jun 1;120(11):1630-8. doi: 10.1002/cncr.28510. Epub 2014 Apr 14.
10
Thoughts on a systematic review and meta-analysis of adjuvant chemotherapy in muscle-invasive bladder cancer.关于肌肉浸润性膀胱癌辅助化疗的系统评价和荟萃分析的思考
Eur Urol. 2014 Jul;66(1):55-6. doi: 10.1016/j.eururo.2014.01.008. Epub 2014 Jan 23.
Zotero 插件